Alentis Therapeutics
Alentis Therapeutics is a clinical-stage biotechnology company based in Basel, Switzerland, focused on developing a pipeline of Claudin-1 (CLDN1) targeted medicines. The company aims to create first-in-class therapies that address unmet medical needs by targeting CLDN1, a key player in various pathological processes.
Leadership & Board
Key Executives
- CEO
- Andrea Pellacani
- CEO
- Roberto Iacone
- Chief Executive Officer
- Mark Pruzanski
- Chief Business Officer
- Rizwan Velji
- Current Number of Employees
- 73
- Current LinkedIn Followers
- 15,935
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $181M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $181M
- Latest Funding Round
- Series D
- Post-Money Valuation
- ―
Company Momentum Positive
Alentis Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Alentis Therapeutics had 73 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Alentis Therapeutics had 15,935 followers as of October 12, 2026. The number of followers increased by 329 (2.11%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series D | $181.40M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Novo Holdings | Series D |
Similar Companies
A snapshot of private companies similar to Alentis Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
